Precigen (PGEN) Other Accumulated Expenses (2012 - 2026)
Precigen (PGEN) posted quarterly Other Accumulated Expenses of $12.5 million for Q1 2026, up 90.03% year-over-year from $6.6 million in Q1 2025, and up 13.54% quarter-over-quarter from $11.0 million in Q4 2025.
Analysis
Precigen (PGEN) Other Accumulated Expenses (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Other Accumulated Expenses for 15 consecutive years, with $12.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 90.03% year-over-year to $12.5 million; the TTM figure through Mar 2026 stood at $12.5 million (up 90.03% YoY), while the FY2025 annual figure was $11.0 million, up 128.45% from the prior year.
- Other Accumulated Expenses rose to $12.5 million in Q1 2026 per PGEN's latest filing, from $11.0 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $22.9 million in Q1 2023 and bottomed at $3.3 million in Q2 2023.
- Historically, Other Accumulated Expenses has averaged $8.7 million across 5 years, with a median of $7.3 million in 2024.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses sank 68.12% — and 2025, when it surged 128.45%.
- Precigen's Other Accumulated Expenses stood at $5.0 million in 2022, then rose by 24.53% to $6.2 million in 2023, then decreased by 22.67% to $4.8 million in 2024, then soared by 128.45% to $11.0 million in 2025, then increased by 13.54% to $12.5 million in 2026.
- Business Quant data shows PGEN's Other Accumulated Expenses at $12.5 million in Q1 2026, $11.0 million in Q4 2025, and $10.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.21 Mn |
| Mar 31, 2026 | 12.48 Mn |
| Dec 31, 2025 | 10.99 Mn |
| Sep 30, 2025 | 10.82 Mn |
| Jun 30, 2025 | 9.51 Mn |
| Mar 31, 2025 | 6.57 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 5.68 Mn |
| Jun 30, 2024 | 6.64 Mn |
| Mar 31, 2024 | 7.30 Mn |
| Dec 31, 2023 | 6.22 Mn |
| Sep 30, 2023 | 4.12 Mn |
| Jun 30, 2023 | 3.26 Mn |
| Mar 31, 2023 | 22.89 Mn |
| Dec 31, 2022 | 5.00 Mn |
| Sep 30, 2022 | 11.69 Mn |
| Jun 30, 2022 | 9.67 Mn |
| Mar 31, 2022 | 10.49 Mn |
| Dec 31, 2021 | 7.82 Mn |
| Sep 30, 2021 | 11.26 Mn |